My response, published today on STAT, to Feuerstein's story on leronlimab:

This one-sided and completely slanted story leaves out important details such as the 60-plus patients treated with leronlimab on an emergency basis at prestigious hospitals, such as Montefiore, Novant, and UCLA, where the well-respected treating physicians, who administered leronlimab to their COVID-19 patients, attributed successful outcomes to this drug.

This story also leaves out the bloodwork analysis of leronlimab-treated COVID-19 patients by respected virologist Dr. Bruce Patterson, who claims leronlimab is the only drug that quells the cytokine storm, reduces the COVID-19 viral load, and helps restore the immune system in COVID-19 patients.

With respect to Nader Pourhassan's neutral comment that he cannot predict the outcome of ongoing COVID-19 clinical trials for leronlimab, no other credible answer was possible given that the trials are double-blinded, which is what Pourhassan correctly noted in his answer to this question.

Finally, it would be helpful to know whether you are short Cytodyn, which, if is the case, suggests a bias that should be disclosed.

LM